Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Fosun Pharmaceutical (Group) CoSFOSF 76 3-Year EBITDA Growth Rate is 7.30% as of Mar. 2026, which is 47% below its 10-year median of 13.90. GuruFocus rates SFOSF with a GF Score™ of 76/100 and a GF Value™ of $2.79 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 814 Drug Manufacturers companies, Shanghai Fosun Pharmaceutical (Group) Co ranks worse than 52.33% on this metric.
During the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co's average EBITDA Per Share Growth Rate was 7.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.40% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shanghai Fosun Pharmaceutical (Group) Co was 105.70% per year. The lowest was -9.20% per year. And the median was 13.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Shanghai Fosun Pharmaceutical (Group) Co 3-Year EBITDA Growth Rate Related Terms
SFOSF vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's 3-Year EBITDA Growth Rate falls into.
Shanghai Fosun Pharmaceutical (Group) Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.30% mean?
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a 3-Year EBITDA Growth Rate of 7.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 47% below median its historical median of 13.90. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #426 out of 814 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Shanghai Fosun Pharmaceutical (Group) Co's 3-Year EBITDA Growth Rate too high?
Shanghai Fosun Pharmaceutical (Group) Co's current 3-Year EBITDA Growth Rate of 7.30% is 47% below median its 10-year median of 13.90. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.85. Shanghai Fosun Pharmaceutical (Group) Co's value of 7.30% is 17.5% below this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #426 out of 814 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #426 out of 814 companies for 3-Year EBITDA Growth Rate. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.85. Shanghai Fosun Pharmaceutical (Group) Co's value of 7.30% is 17.5% below this benchmark. While the company's 10-year median is 13.90 vs. the industry median of 8.85, Shanghai Fosun Pharmaceutical (Group) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.85, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current 3-Year EBITDA Growth Rate of 7.30% is 17.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current 3-Year EBITDA Growth Rate is 7.30%, which is 47% below median its own 10-year median of 13.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.79, compared to a current price of $2.20 — trading 21.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.30%, which is 47% below median its 10-year median of 13.90 and 17.5% below the Drug Manufacturers industry median of 8.85. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current 3-Year EBITDA Growth Rate is 7.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 21.1% below its estimated GF Value™ of $2.79.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
3-Year EBITDA Growth Rate: 7.30% (47% below median its 10-year median of 13.90)
GF Value™: $2.79 vs. price of $2.20 (21.1% below fair value)
Industry Position: 17.5% below the Drug Manufacturers median (#426 of 814)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
76GF Score
Get the complete analysis for SFOSF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
